Intra-nodal Injection of Gentamicin for the Treatment of Suppurated Cat Scratch Disease's Lymphadenitis (BIGG)
Primary Purpose
Cat-Scratch Disease
Status
Recruiting
Phase
Phase 3
Locations
France
Study Type
Interventional
Intervention
gentamicin
placebo
Sponsored by

About this trial
This is an interventional treatment trial for Cat-Scratch Disease focused on measuring Cat Scratch Disease's lymphadenitis, Infectious Diseases
Eligibility Criteria
Inclusion Criteria:
- Informed consent
Suppurated CSD's adenitis:
- Suppurated form of adenitis confirmed by echography
- Serology positive for Immunoglobulin G and/or Immunoglobulin M against B. henselae
Exclusion Criteria:
- Suppurated adenitis non related to CSD
- Non-suppurated CSD's adenitis
- Suppurated CSD's adenitis already fistulized
- Suspected visceral B. henselae infection (neurologic or ophthalmic symptoms, hepato-splenic or valvular involvement confirmed by echography)
- Immunodepression (except diabetes)
- Pregnancy
- Contraindication to pus aspiration from lymphadenitis (history of bleeding or patient taking curative anticoagulation therapy or platelet count < 50.000/mm3)
- Contraindication to azithromycin (history of QT interval prolongation, history of liver toxicity of hypersensitivity to macrolides or treatment with ergotamine, dihydroergotamine, bepridil, cisapride, pimozide, mizolastine or colchicine) or to aminoglycosides (myasthenia, history of hypersensitivity to aminoglycosides).
Sites / Locations
- Albi HospitalRecruiting
- Amiens-Picardie HospitalRecruiting
- Angers HospitalRecruiting
- Auch HospitalRecruiting
- Bordeaux University HospitalRecruiting
- Cahors HospitalRecruiting
- Castres HospitalRecruiting
- Vendée HospitalRecruiting
- Limoges University HospitalRecruiting
- Hospices Civils LyonRecruiting
- Montauban HospitalRecruiting
- Montpellier University HospitalRecruiting
- Nîmes University HospitalRecruiting
- Pau HospitalRecruiting
- Perpignan HospitalRecruiting
- Rennes HospitalRecruiting
- Rodez HospitalRecruiting
- Saint-Brieuc HospitalRecruiting
- Saint-Nazaire HospitalRecruiting
- Tarbes HospitalRecruiting
- Microbiology LaboratoryRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Gentamicin
Placebo
Arm Description
intra-nodal injection of gentamicin
intra-nodal injection of placebo
Outcomes
Primary Outcome Measures
Frequency at day 28 of CSD's adenitis favorable outcome
Adenitis favorable outcome characterized as : Reduction of the volume of the adenitis, Without requirement of supplementary needle aspirations after day 7's visit, And without requirement of a surgical excision or incision of the adenitis.
Secondary Outcome Measures
Reduction of the adenitis
Percentage of volume reduction of the adenitis
Evaluation of the pain related to the adenitis
Percentage of reduction of the pain related to the adenitis
Fistulization of the adenitis
Number of patients with persisting cutaneous fistulization of the adenitis
Surgical action
Number of patients requiring surgical excision or incision of the adenitis
Protein C reactive
Percentage of decrease of serum Protein C reactive
Antibiotic resistance
Genotypic profile of resistance to macrolides and aminoglycosides
Safety of treatment
Incidence of Treatment-Emergent Events linked to the study treatment
Full Information
NCT ID
NCT03132116
First Posted
March 5, 2017
Last Updated
July 27, 2023
Sponsor
University Hospital, Toulouse
1. Study Identification
Unique Protocol Identification Number
NCT03132116
Brief Title
Intra-nodal Injection of Gentamicin for the Treatment of Suppurated Cat Scratch Disease's Lymphadenitis
Acronym
BIGG
Official Title
Intra-nodal Injection of Gentamicin for the Treatment of Suppurated Cat Scratch Disease's Lymphadenitis: A Randomized Controlled Study
Study Type
Interventional
2. Study Status
Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 31, 2017 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Toulouse
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
To compare effect of intra-nodal injection of gentamicin versus placebo on the outcome at 28 days of suppurated cat scratch disease's (CSD) lymphadenitis treated by oral azithromycin.
Detailed Description
Double blind controlled study versus placebo. Patients with suppurated CSD's lymphadenitis will receive immediately after the pus aspiration (performed for a diagnostic purpose) an intra-nodal injection of gentamicin or of placebo (NaCl 0,9%) and be treated with oral azithromycin for 5 days.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cat-Scratch Disease
Keywords
Cat Scratch Disease's lymphadenitis, Infectious Diseases
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
100 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Gentamicin
Arm Type
Experimental
Arm Description
intra-nodal injection of gentamicin
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
intra-nodal injection of placebo
Intervention Type
Drug
Intervention Name(s)
gentamicin
Intervention Description
After inclusion in the study, patient will be randomized. According to randomization, patient will receive an intra-nodal injection of gentamicin .
As well, azithromycin will be prescribed for all patients for 5 days. Patients will be followed-up each week until week 4 (Day 28).
Intervention Type
Drug
Intervention Name(s)
placebo
Other Intervention Name(s)
NaCl
Intervention Description
After inclusion in the study, patient will be randomized. According to randomization, patient will receive an intra-nodal injection of placebo.
As well, azithromycin will be prescribed for all patients for 5 days. Patients will be followed-up each week until week 4 (Day 28).
Primary Outcome Measure Information:
Title
Frequency at day 28 of CSD's adenitis favorable outcome
Description
Adenitis favorable outcome characterized as : Reduction of the volume of the adenitis, Without requirement of supplementary needle aspirations after day 7's visit, And without requirement of a surgical excision or incision of the adenitis.
Time Frame
Day 28
Secondary Outcome Measure Information:
Title
Reduction of the adenitis
Description
Percentage of volume reduction of the adenitis
Time Frame
from Day 0 to Day 28
Title
Evaluation of the pain related to the adenitis
Description
Percentage of reduction of the pain related to the adenitis
Time Frame
between Day 0, Day 7 and Day 28
Title
Fistulization of the adenitis
Description
Number of patients with persisting cutaneous fistulization of the adenitis
Time Frame
Day 7 and day 28
Title
Surgical action
Description
Number of patients requiring surgical excision or incision of the adenitis
Time Frame
Day 28
Title
Protein C reactive
Description
Percentage of decrease of serum Protein C reactive
Time Frame
Day 0 and day 7
Title
Antibiotic resistance
Description
Genotypic profile of resistance to macrolides and aminoglycosides
Time Frame
Day 28
Title
Safety of treatment
Description
Incidence of Treatment-Emergent Events linked to the study treatment
Time Frame
Day 7 and day 28
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Informed consent
Suppurated CSD's adenitis:
Suppurated form of adenitis confirmed by echography
Serology positive for Immunoglobulin G and/or Immunoglobulin M against B. henselae
Exclusion Criteria:
Suppurated adenitis non related to CSD
Non-suppurated CSD's adenitis
Suppurated CSD's adenitis already fistulized
Suspected visceral B. henselae infection (neurologic or ophthalmic symptoms, hepato-splenic or valvular involvement confirmed by echography)
Immunodepression (except diabetes)
Pregnancy
Contraindication to pus aspiration from lymphadenitis (history of bleeding or patient taking curative anticoagulation therapy or platelet count < 50.000/mm3)
Contraindication to azithromycin (history of QT interval prolongation, history of liver toxicity of hypersensitivity to macrolides or treatment with ergotamine, dihydroergotamine, bepridil, cisapride, pimozide, mizolastine or colchicine) or to aminoglycosides (myasthenia, history of hypersensitivity to aminoglycosides).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Guillaume MARTIN-BLONDEL, MD, PhD
Phone
+33 (0) 5 61 77 96 99
Email
martin-blondel.g@chu-toulouse.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Alexa DEBARD, MD
Phone
+33 (0) 5 61 77 95 86
Email
debard.a@chu-toulouse.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Guillaume MARTIN-BLONDEL, MD, PhD
Organizational Affiliation
University Hospital of Toulouse, Infectious & Tropical Diseases department
Official's Role
Principal Investigator
Facility Information:
Facility Name
Albi Hospital
City
Albi
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marie-Anne LAFFONT, MD
Facility Name
Amiens-Picardie Hospital
City
Amiens
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jean-Luc SCHMIT, MD
Facility Name
Angers Hospital
City
Angers
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vincent DUBEE, MD
Facility Name
Auch Hospital
City
Auch
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sophie ARISTA, MD
Facility Name
Bordeaux University Hospital
City
Bordeaux
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michel DUPON, MD
First Name & Middle Initial & Last Name & Degree
Michel DUPON, MD
First Name & Middle Initial & Last Name & Degree
Estibaliz LAZARO, MD
First Name & Middle Initial & Last Name & Degree
Fabrice BONNET, MD
Facility Name
Cahors Hospital
City
Cahors
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stéphane SIRE, MD
Facility Name
Castres Hospital
City
Castres
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Florence-Sarah KHATIBI, MD
Facility Name
Vendée Hospital
City
La Roche-sur-Yon
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thomas GUIMARD, MD
Facility Name
Limoges University Hospital
City
Limoges
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pierre WEINBRECK, MD
Facility Name
Hospices Civils Lyon
City
Lyon
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Florence ADER, MD
Facility Name
Montauban Hospital
City
Montauban
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marc DELAVAISSIERE, MD
Facility Name
Montpellier University Hospital
City
Montpellier
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
David MORQUIN, MD
Facility Name
Nîmes University Hospital
City
Nîmes
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Catherine LECHICHE, MD
Facility Name
Pau Hospital
City
Pau
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Valérie GABORIEAU, MD
Facility Name
Perpignan Hospital
City
Perpignan
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Léa COLOMBAIN, MD
Facility Name
Rennes Hospital
City
Rennes
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Matthieu REVEST, MD
Facility Name
Rodez Hospital
City
Rodez
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bruno GUERIN, MD
Facility Name
Saint-Brieuc Hospital
City
Saint-Brieuc
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rodolphe BUZELE, MD
Facility Name
Saint-Nazaire Hospital
City
Saint-Nazaire
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Julia BROCHARD, MD
Facility Name
Tarbes Hospital
City
Tarbes
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Florian BUSATO, MD
Facility Name
Microbiology Laboratory
City
Toulouse
ZIP/Postal Code
31059
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Guillaume MARTIN-BLONDEL, MD
First Name & Middle Initial & Last Name & Degree
Guillaume MARTIN-BLONDEL, MD,PhD
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Intra-nodal Injection of Gentamicin for the Treatment of Suppurated Cat Scratch Disease's Lymphadenitis
We'll reach out to this number within 24 hrs